Compare STEM & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | CYPH |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 73.4M |
| IPO Year | 2020 | N/A |
| Metric | STEM | CYPH |
|---|---|---|
| Price | $6.98 | $0.71 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $13.33 | N/A |
| AVG Volume (30 Days) | 95.6K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | N/A |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $14.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $6.70 | $0.49 |
| 52 Week High | $32.23 | $3.70 |
| Indicator | STEM | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 47.30 |
| Support Level | N/A | $0.55 |
| Resistance Level | $8.39 | $0.81 |
| Average True Range (ATR) | 0.48 | 0.07 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 15.32 | 64.19 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.